查看购物车
  • Traditional Chinese
  • English
  • Japanese
  • Korean
封面
市场调查报告书
商品编码
1197362

肾功能检测市场 - COVID-19 的增长、趋势、影响和预测 (2023-2028)

Kidney Function Tests Market - Growth, Trends, and Forecasts (2023 - 2028)
出版日期: | 出版商: Mordor Intelligence | 英文 120 Pages | 商品交期: 2-3个工作天内

价格

※ 本网页内容可能与最新版本有所差异。详细情况请与我们联繫。

简介目录

在 2022 年至 2027 年的预测期内，肾功能检测市场的复合年增长率预计为 5.62%。

COVID-19 随着疾病的进展影响患者的肾功能，因此大流行对肾功能检测市场产生了重大影响。 根据 2020 年 11 月发表的一项题为“Association of Proteinuria and Hematuria with Acute Kidney Injury and Mortality in Hospitalized Patients with COVID-19”的研究，超过 40% 的 COVID-19 住院患者有蛋白尿和血尿等症状。据说观察到肾功能障碍的症状。 此外，根据一项名为“新生儿和儿科的 COVID-19 感染”的研究，“COVID-19 感染的临床特征。据报导，19 引起的尿失禁在中度至重度患者中很常见。 在儿童中，已报告轻度 COVID-19 患者接触过 COVID-19。 发病后第1天至第52天确认尿路感染。 这种情况在大流行期间对市场增长率产生了显着影响。

此外，慢性肾脏病的增加，糖尿病、高血压等导致肾臟损害的基础疾病的增加，肾功能诊断方法意识的提高，诊断设备和工具的技术进步等因素，推动市场的增长，这是一个激励因素。

糖尿病和高血压被认为是导致全球慢性肾脏病负担增加的主要因素。 糖尿病患者数量的增加最终将影响预测期内的市场增长。 例如，根据 2021 年第 10 版国际糖尿病地图集，5.37 亿成年人（20-79 岁）患有糖尿病，其中大约十分之一患有糖尿病。 这一数字预计到 2030 年将增加到 6.43 亿，到 2045 年将增加到 7.83 亿。

此外，市场参与者正在采取各种策略，例如产品发布、产品开发、合作伙伴关係、收购、整合和扩展，以最大限度地扩大其在全球的地理覆盖范围。 例如，2020 年 8 月，RenalytixAI 获得美国食品和药物管理局 (FDA) 批准用于新的 KidneyIntelX 测试。 人工智能驱动的临床试验旨在识别和改善 2 型糖尿病和快速进展的肾臟疾病患者的临床管理。 预计技术先进产品的出现将在预测期内进一步推动市场增长。

因此，上述因素可能会对市场的增长产生积极影响。 然而，诊断程序的高成本和严格的法规预计将在不久的将来阻碍肾功能检测市场的增长。

肾功能检测的市场趋势

在肾功能检测市场，试纸板块有望占据主要市场份额

量油尺是一种塑料棒，上面附有一系列化学物质。 将此试纸浸入尿液中，当色带变色时，表明存在异常物质，例如蛋白质、血液、发红、细菌和糖分。 这使我们能够识别广泛的肾臟和泌尿系统问题，例如慢性肾臟疾病、急性肾损伤、膀胱疾病和肾结石。

美国国立卫生研究院 (NIH) 报告说，大多数患有严重 COVID-19 急性肾损伤 (AKI) 的患者在康復后继续进行下肾臟治疗。 2022 年 2 月发表的一项题为“使用试纸尿液分析预测 COVID-19 患者肾臟损伤的发展”的研究发现，试纸尿液分析中的蛋白尿和血尿水平与住院期间的 COVID-19 相关。已发现它可用于预测 19 名患者的 AKI 和肾臟替代治疗 (RRT)。 同样，美国国家肾臟基金会于 2020 年 3 月发布的一份报告指出，住院的 COVID-19 患者患严重肾损伤 (AKI) 的风险增加，这可能导致重病和死亡。我来了。 在一项类似的研究中，与 2019 年同时发生 AKI 的非 COVID 患者相比，2020 年 3 月 11 日至 4 月 26 日住院的 COVID-19 患者发生了 AKI。发生这种情况的机率翻了一番，计算为 56.9% 对 25.1% ％， 分别。 因此，由于易于诊断和产品可用性，预计 COVID-19导致的肾衰竭和慢性肾衰竭发病率上升将在预测期内推动该细分市场的增长。

此外，2021 年 8 月，总部位于西雅图的 ID Genomics (IDG) 将发明一种基于试纸的检测方法，以同时识别 SARS-CoV2 中的多个基因突变，而国家卫生部已从美国国家研究院获得 300,000 美元的资助卫生部 (NIH)。

此外，政府对肾功能障碍的举措和投资的更多关注以及肾臟疾病的新疗法将促进这一细分市场的增长。 例如，2020 年 1 月，瑞典的 Elypta AB 筹集了 700 万美元用于尿癌筛查测试。

因此，由于上述因素，该细分市场在预测期内可能会出现增长。

北美主导市场，预计在预测期内将继续保持这一势头

北美地区的市场增长是由改善的医疗保健基础设施、增加的尿路感染髮病率以及更广泛使用的诊断测试推动的。

冠状病毒正在对该地区产生重大影响，尤其是在美国。 2020 年，约翰霍普金斯大学肾脏病学系建议应对与 COVID-19 相关的肾臟损伤进行检测，以确保肾功能恢復正常。 因此，预计该地区 COVID-19负担的增加将增加对肾臟检测的需求，从而对市场增长产生积极影响。 此外，根据卫生资源服务局的数据，到 2022 年 2 月，美国将进行大约 26,640 例肾臟移植手术。 如此大量的移植导致需要进行移植后肾功能检测以检测正常肾功能，从而推动市场增长。

此外，肾臟疾病负担的增加及其根本原因预计将推动北美市场的增长。 例如，根据肾臟基金会发布的 2020 年报告，加拿大约有 400 万人患有肾臟疾病，其中 46% 的新病例年龄在 65 岁以下。 自 2009 年以来，患有终末期肾病的人数增加了 35%。 因此，该地区这些疾病的高负担预计会增加对肾功能检测的需求。

此外，2022 年 7 月，bioMerieux 获得了美国食品和药物管理局的许可，其创新的 VIDAS NEPHROCHECK 检测方法可检测有急性肾损伤 (AKI) 风险的患者的肾臟压力。 该地区新产品的推出和尿液分析的不断进步正在推动市场增长。

因此，由于上述因素，预计北美地区的市场增长。

肾功能检测市场竞争对手分析

肾功能检测市场的竞争是分散的，由几家大公司组成。 从市场份额的角度来看，一些主要参与者目前主导着市场。 目前主导市场的公司包括 F. Hoffmann-La Roche Ltd.、ACON Laboratories Inc.、77 Elektronika Kft、Nova Biomedical 和 Quest Diagnostics。

其他好处

  • Excel 格式的市场预测 (ME) 表
  • 三个月的分析师支持

内容

第一章介绍

  • 研究假设和市场定义
  • 调查范围

第二章研究方法论

第 3 章执行摘要

第四章市场动态

  • 市场概览
  • 市场驱动因素
    • 慢性肾脏病患病率上升
    • 提高对肾臟正常功能诊断方法的认识
    • 诊断机器和仪器的技术进步
  • 市场製约因素
    • 诊断程序的高成本
    • 严格监管
  • 波特的五力分析
    • 新进入者的威胁
    • 买方/消费者议价能力
    • 供应商的议价能力
    • 替代品的威胁
    • 竞争公司之间的敌对关係

第 5 章市场细分（基于价值的市场规模 - 百万美元）

  • 按产品类型
    • 滴管
    • 一次性的
    • 试剂
  • 按测试类型
    • 尿液分析试剂
      • 尿蛋白测试
      • 用于测量肌酐清除率
      • 微量白蛋白测量
    • 验血
      • 血清肌酐测量
      • 肾小球滤过率测试
      • 血尿素氮测量
  • 最终用户
    • 医院和诊所
    • 诊断机构
    • 其他最终用户
  • 按地区
    • 北美
      • 美国
      • 加拿大
      • 墨西哥
    • 欧洲
      • 德国
      • 英国
      • 法国
      • 意大利
      • 西班牙
      • 其他欧洲地区
    • 亚太地区
      • 中国
      • 日本
      • 印度
      • 澳大利亚
      • 韩国
      • 其他亚太地区
    • 中东
      • 海湾合作委员会
      • 南非
      • 其他中东地区
    • 南美洲
      • 巴西
      • 阿根廷
      • 其他南美洲

第六章竞争格局

  • 公司简介
    • F.Hoffmann-La Roche Ltd
    • URIT Medical Electronic Co. Ltd
    • Arkray Inc.
    • Abbott Laboratories
    • Nova Biomedical
    • Sysmex Corporation
    • ACON Laboratories Inc.
    • 77 Elektronika Kft
    • Randox Laboratories
    • Quest Diagnostics
    • bioMerieux SA
    • Laboratory Corporation of America Holdings

第7章 市场机会今后动向

简介目录
Product Code: 68015

The Kidney Function Tests Market is expected to register a CAGR of 5.62% during the forecast period, 2022-2027.

The pandemic has significantly impacted the kidney function tests market, as COVID-19 affected the patients' kidney function with the disease progression. According to a study titled "Association of Proteinuria and Hematuria with Acute Kidney Injury and Mortality in Hospitalized Patients with COVID-19" published in November 2020, more than 40% of admitted patients with COVID-19 showed symptoms of abnormal kidney function, such as albuminuria or hematuria. Furthermore, according to a study titled "Clinical Characteristics of COVID-19 Infection in Newborns and Pediatrics: A Systematic Review" published in April 2020, in adult patients, COVID-19 urinary incontinence was commonly found in patients with moderate to severe conditions. In children, exposure to COVID-19 has been reported among those who suffer from a mild form of COVID-19. From the onset of the disease, urinary tract infections were identified from day 1 to day 52. Thus, such instances notably impacted the growth rate of the market over the pandemic phase.

Furthermore, some of the factors driving the growth of the market include an increase in chronic kidney disease; the growing prevalence of underlying conditions such as diabetes and hypertension leading to kidney disorders; an increase in awareness about diagnostic methods for kidney function; and technological advances in diagnostic equipment and tools.

Diabetes and high blood pressure are considered major factors responsible for the growing burden of chronic kidney disease worldwide. Growing cases of diabetes will ultimately impact the growth of the market over the forecast period. For instance, according to the International Diabetes Atlas tenth edition in 2021, 537 million adults (20-79 years) were living with diabetes, approximately 1 in 10 individuals. This number is predicted to rise to 643 million by 2030 and 783 million by 2045.

Additionally, market players embrace a variety of strategies such as product launches, product developments, collaborations, acquisitions, integrations, and expansion to maximize their geographical reach worldwide. For example, in August 2020, RenalytixAI received approval from the United States Food and Drug Administration (FDA) for its new KidneyIntelX test. AI-enabled clinical trials are designed to identify and improve the clinical management of patients with type 2 diabetes and rapidly progressive kidney disease. The emergence of technologically advanced products is expected to further boost the market's growth over the forecast period.

Thus, the aforesaid factors are likely to have a positive impact on the market's growth. However, the high cost of diagnostic procedures and strict regulations are expected to hamper the kidney function tests market's growth in the near future.

Kidney Function Tests Market Trends

Dipstick Segment is Expected to Hold a Major Market Share in the Kidney Function Tests Market

The dipstick is a type of plastic stick that has a chemical line on it in the form of lines. The dipstick is dipped in urine, and when the color of the ribbon changes, it indicates the presence of abnormal substances such as protein, blood, redness, bacteria, and sugar. This helps to identify a range of kidney and urinary problems, such as chronic kidney disease, acute kidney injuries, bladder diseases, and kidney stones, among others.

The National Institute of Health (NIH) reported that most patients with serious COVID-19 acute kidney injury (AKI) complications are still working on their lower kidneys after recovery. According to the study titled "Using dipstick urinalysis to predict the development of kidney damage in patients with COVID-19" published in February 2022, the levels of proteinuria and hematuria in dipstick urine analysis can be used to predict AKI and renal replacement therapy (RRT) in hospitalized COVID-19 patients. Likewise, a report published by the National Kidney Foundation Inc. in March 2020 stated that hospitalized people with COVID-19 were at a higher risk of serious kidney injury (AKI), which could lead to serious illness and even death. A similar study found that patients with COVID-19, who were hospitalized between March 11 and April 26, 2020, were twice as likely to develop AKI compared to non-COVID patients who developed AKI simultaneously in 2019, which was calculated at 56.9% compared to 25.1%, respectively. Therefore, an increase in the incidence of kidney failure and chronic kidney failure due to COVID-19 is expected to promote the segment's growth during the forecast period due to ease of diagnosis and availability of products.

Moreover, in August 2021, ID Genomics (IDG), a Seattle-based company, invented a dipstick-based assay for the simultaneous identification of a large number of genetic variants of SARS-CoV2 and received a grant of USD 300,000 from the National Institute of Health (NIH).

Furthermore, rising government efforts to address improper kidney functions, growing investments, and newer treatments for kidney disease are at the forefront, which will in turn bolster the segment's growth. For example, in January 2020, Sweden's Elypta AB collected a USD 7.0 million fund for a urine cancer screening test.

Therefore, due to these abovementioned factors, the segment may witness growth during the forecast period.

North America Dominates the Market and is Expected to Continue the Same Over the Forecast Period

Some of the factors driving the growth of the market in the North American region include better health care infrastructure, an increase in urinary tract infections, and more widely available diagnostic tests.

The coronavirus has had a significant impact in the region, particularly in the United States. The Johns Hopkins Division of Nephrology, in 2020, suggested that COVID-19-related kidney damage should be followed by tests to ensure kidney function returns to normal. Therefore, the growing burden of COVID-19 in the region is expected to increase the need for kidney tests, thereby positively impacting the market's growth. Moreover, according to the Health Resources & Services Administration, in February 2022 in the United States, about 26,640 kidney transplants were performed. Such a high number of transplants creates the need for kidney function tests post-transplantation procedures to detect the proper functioning of the kidneys and thus drives the growth of the market.

Moreover, the growing burden of kidney diseases and their underlying causes are anticipated to boost market growth in North America. For instance, in 2020, a report published by the Kidney Foundation stated that around 4 million people have kidney disease in Canada, of which 46% of new patients are under the age of 65. In addition, the number of people living with end-stage kidney disease has grown by 35% since 2009. This significant burden of these diseases in the region is expected to augment the demand for kidney function tests.

Additionally, in July 2022, bioMerieux received United States Food and Drug Administration clearance for the innovative VIDAS NEPHROCHECK assay to detect kidney stress in patients at risk of acute kidney injury (AKI). The introduction of new products and the growing advances in urine analysis in the region are boosting the market's growth.

Therefore, owing to the abovementioned factors, the market is expected to grow in the North American region.

Kidney Function Tests Market Competitor Analysis

The Kidney Function Tests Market is fragmented in terms of competition and consists of several major players. In terms of market share, a few major players are currently dominating the market. Some companies currently dominating the market include F.Hoffmann-La Roche Ltd., ACON Laboratories Inc., 77 Elektronika Kft, Nova Biomedical, and Quest Diagnostics.

Additional Benefits:

  • The market estimate (ME) sheet in Excel format
  • 3 months of analyst support

TABLE OF CONTENTS

1 INTRODUCTION

  • 1.1 Study Assumptions and Market Definition
  • 1.2 Scope of the Study

2 RESEARCH METHODOLOGY

3 EXECUTIVE SUMMARY

4 MARKET DYNAMICS

  • 4.1 Market Overview
  • 4.2 Market Drivers
    • 4.2.1 Rising Prevalence of Chronic Kidney Diseases
    • 4.2.2 Increasing Awareness about the Diagnostic Methods for the Proper Functioning of the Kidney
    • 4.2.3 Technological Advancements in Diagnostic Machinery and Tools
  • 4.3 Market Restraints
    • 4.3.1 High Cost of Diagnostic Procedures
    • 4.3.2 Stringent Regulations Norms
  • 4.4 Porter's Five Forces Analysis
    • 4.4.1 Threat of New Entrants
    • 4.4.2 Bargaining Power of Buyers/Consumers
    • 4.4.3 Bargaining Power of Suppliers
    • 4.4.4 Threat of Substitute Products
    • 4.4.5 Intensity of Competitive Rivalry

5 MARKET SEGMENTATION (Market Size by Value - USD Million)

  • 5.1 By Product Type
    • 5.1.1 Dipsticks
    • 5.1.2 Disposables
    • 5.1.3 Reagents
  • 5.2 By Test Type
    • 5.2.1 Urine Tests
      • 5.2.1.1 Urine Protein Tests
      • 5.2.1.2 Creatinine Clearance Tests
      • 5.2.1.3 Microalbumin Tests
    • 5.2.2 Blood Tests
      • 5.2.2.1 Serum Creatinine Tests
      • 5.2.2.2 Glomerular Filtration Rate Tests
      • 5.2.2.3 Blood Urea Nitrogen Tests
  • 5.3 By End User
    • 5.3.1 Hospitals and Clinics
    • 5.3.2 Diagnostic Laboratories
    • 5.3.3 Other End Users
  • 5.4 Geography
    • 5.4.1 North America
      • 5.4.1.1 United States
      • 5.4.1.2 Canada
      • 5.4.1.3 Mexico
    • 5.4.2 Europe
      • 5.4.2.1 Germany
      • 5.4.2.2 United Kingdom
      • 5.4.2.3 France
      • 5.4.2.4 Italy
      • 5.4.2.5 Spain
      • 5.4.2.6 Rest of Europe
    • 5.4.3 Asia-Pacific
      • 5.4.3.1 China
      • 5.4.3.2 Japan
      • 5.4.3.3 India
      • 5.4.3.4 Australia
      • 5.4.3.5 South Korea
      • 5.4.3.6 Rest of Asia-Pacific
    • 5.4.4 Middle East
      • 5.4.4.1 GCC
      • 5.4.4.2 South Africa
      • 5.4.4.3 Rest of Middle East
    • 5.4.5 South America
      • 5.4.5.1 Brazil
      • 5.4.5.2 Argentina
      • 5.4.5.3 Rest of South America

6 COMPETITIVE LANDSCAPE

  • 6.1 Company Profiles
    • 6.1.1 F.Hoffmann-La Roche Ltd
    • 6.1.2 URIT Medical Electronic Co. Ltd
    • 6.1.3 Arkray Inc.
    • 6.1.4 Abbott Laboratories
    • 6.1.5 Nova Biomedical
    • 6.1.6 Sysmex Corporation
    • 6.1.7 ACON Laboratories Inc.
    • 6.1.8 77 Elektronika Kft
    • 6.1.9 Randox Laboratories
    • 6.1.10 Quest Diagnostics
    • 6.1.11 bioMerieux SA
    • 6.1.12 Laboratory Corporation of America Holdings

7 MARKET OPPORTUNITIES AND FUTURE TRENDS